SCHEMBL27186166

SCHEMBL27186166

C[Si](C)(C)CCOCn1ncc2c(=O)n(C3CCOCC3)cc(I)c21

nearest known ligand 0.32

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PDE1A P54750 10/20 0.32
▸ PDE1B Q01064 10/20 0.32
▸ PDE1C Q14123 10/20 0.32
▸ PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27186178 0.86 JAK1 (0.35) PDE4D
SCHEMBL27186123 0.84 PDE4B (0.35) PDE1APDE1BPDE1C
SCHEMBL27186151 0.80 PDE1B (0.38) PDE1APDE1BPDE1CPDE4D
SCHEMBL27186086 0.71 JAK1 (0.35) PDE4D
SCHEMBL27186175 0.69 KDM4E (0.32) —
SCHEMBL30853341 0.69 — —
SCHEMBL30481822 0.68 ALOX5AP (0.31) —
SCHEMBL15770814 0.67 DGAT1 (0.35) —
SCHEMBL27186184 0.67 NPC1 (0.34) —
SCHEMBL27186361 0.67 NPC1 (0.31) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2024-04-04 — — US disclosed
CN-117651701-A Novel substituted bicyclic aza heterocycles as SOS1 inhibitors 唯久生物技术(苏州)有限公司 2024-03-05 — — CN disclosed
WO-2022187266-A1 NOVEL SUBSTITUTED BICYCLI AZA-HETEROCYCLES AS SOS1 INHIBITORS VIVA STAR BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2022-09-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109887-A1 NOVEL SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS SOS1, SOS2, KSR1 PDE1A 1247/4885PDE1B 1585/4885PDE1C 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback